Conference Coverage

Expert argues for change in the way biomarkers are evaluated

Publish date: August 27, 2015

 

EXPERT ANALYSIS FROM PMO LIVE

References

Dr. Kattan disclosed that he receives consulting fees from Bayer, Exosome, GlaxoSmithKline, HistoSonics, and Merck.

Pages

Recommended Reading

Weight program effective for breast cancer survivors
MDedge Hematology and Oncology
Ipilimumab’s immune-related adverse effects greater in ‘real-world patients’
MDedge Hematology and Oncology
Antidepressant, anxiolytic use higher among cancer survivors
MDedge Hematology and Oncology
Immune-related patterns of response present challenges
MDedge Hematology and Oncology
Warfarin as effective as LMWH to prevent recurrent VTEs in cancer patients
MDedge Hematology and Oncology
Mixed results for cancer survivorship care plan
MDedge Hematology and Oncology
Re-personalizing precision medicine: is there a role for patient-reported outcomes?
MDedge Hematology and Oncology
Lung cancer in HIV-infected patients and the role of targeted therapy
MDedge Hematology and Oncology
Life-threatening hypoglycemia resulting from a nonislet cell tumor
MDedge Hematology and Oncology
Drug-induced immune hemolytic anemia associated with albumin-bound paclitaxel
MDedge Hematology and Oncology